LA JOLLA, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the Company), an immunology company developing treatments that harness the patients innate immune system to fight disease, today reported its financial results for the fourth quarter and full year ended December 31, 2019 and is providing a business update.
The Company will hold a conference call today at 11AM Eastern (U.S.) time. To participate in the live conference call, please dial 1-877-407-2988 five minutes prior to the scheduled conference call time and ask for the, INmune Bio Conference Call. International callers should dial 1-201-389-0923. Participants can also use this link for instant telephone access to the event.
2019 and Recent Corporate Highlights on the DN-TNF Platform and NK Priming Platform:
-- Closed an initial public offering (IPO) and commenced trading on The Nasdaq Capital Market. -- Added two new independent members to the board of directors; Ed Baracchini former chief business officer of Xencor, Inc. who has negotiated many transactions with pharmaceutical and biotechnology companies and; Marcia Allen, a fortune 500 executive with vast accounting and finance experience.
DN-TNF Platform Highlights:
-- Successfully reported Phase I clinical data that INB03 demonstrates safety and efficacy in cancer patients and has announced that the Phase II program will target trastuzumab resistance in women with HER2+ breast cancer using INB03 as part of combination therapy. -- Awarded a $1,000,000 grant from The Alzheimers Association allowing INMB to initiate a Phase 1 clinical trial using XPro1595 to treat patients with Alzheimers Disease. -- Awarded a $500,000 grant from The ALS Association to complete IND enabling pre-clinical studies with XPro1595 as a therapy for ALS. -- Initiated a program in NASH with LIVNate the third drug development program from the DN-TNF platform, joining DN-TNF platform drug candidates INB03 and XPro1595. -- XPro1595 had 9 articles published in peer review journals by academic collaborators and INB03 was one of 85 abstracts (out of 885) to be given as an oral presentation at SITC2019. -- United States Patent and Trademark Office (USPTO) has issued Patent No. 15/776,061 on January 28, 2020, titled CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR NUCROSIS FACTOR, which covers INmunes INB03 Program utilizing dominant negative TNF (DN-TNF) technology for treating cancer.
NK Priming Platform Highlights:
-- Announced publication of data on INKmune in Peer-Reviewed Journal PLOS ONE. INKmune is a novel NK cell priming platform that signals the patients own NK cells to target residual disease of cancer. -- Finalized and validated manufacturing and distributions processes for INKmune to support up-coming clinical trials.
Professor Lowdell, CSO INmune Bio and Professor of Cell Therapy at UCL, London, and creator of the INKmune product said, 2019 has been a landmark year for this product and is the culmination of 20 years of bench-to-bedside research. We have published the molecular basis of the mechanism of action in a peer-reviewed journal, developed scaled manufacture adequate for full commercial delivery and validated an efficient and easily delivered cold supply chain for the drug. I am extremely excited about our delivery of patients into two phase I trials this year in high risk MDS cancer and ovarian cancer, two very different clinical applications.
2019 and year to date, has been a period of substantial progress, stated RJ Tesi, M.D., Chief Executive Officer of INmune Bio. We completed our first-in-man study of our DN-TNF platform in cancer and have expanded that franchise to include Alzheimers Disease and NASH. Additionally, we just announced pre-clinical proof-of-concept studies in ALS. Both our NK cell priming platform and DN-TNF platform continue to generate data in the laboratory and the clinic to allow us to expand the depth and breadth of our pipeline.
Upcoming Milestones:
-- Report results of Phase 1 XPro1595 in Alzheimers Disease, expected to complete 2H 2020. -- Enroll first patient in Phase II INB03 program, targeting trastuzumab resistant HER2+ breast cancer using INB03 as part of combination therapy, expected mid-2020. -- Enroll first patient in Phase II LIVNate for NASH, expected mid-2020. -- Enroll first patient in Phase I INKmune in High Risk MDS cancer, expected 2H 2020. -- Enroll first patient in Phase I INKmune in Ovarian cancer, expected 2H 2020.
Financial Results for the Fourth Quarter Ended December 31, 2019:
Net loss attributable to common stockholders for the fourth quarter ended December 31, 2019 was $2.3 million, compared to $1.9 million for the quarter ended December 31, 2018.
Research and development expense totaled approximately $0.9 million for the fourth quarter ended December 31, 2019, compared with approximately $1.0 million for the quarter ended December 31, 2018. The decrease in research and development expense was due to the Company recording $0.3 million of contra research and development expense as a result of the receipt of a grant from the Alzheimers Association. Excluding the grant, research and development expense increased during the three months ended December 31, 2019 as a result of the further advancement of our drug platforms.
General and administrative expense was approximately $1.5 million in the quarter ended December 31, 2019, compared to approximately $0.9 million in the quarter ended December 31, 2018. The $0.6 million increase in general and administrative expense is largely due to the costs associated with being a public company and due to higher compensation cost (including higher stock-based compensation).
At December 31, 2019, the Company had cash and cash equivalents of approximately $7.0 million with no debt. During the quarter ending December 31, 2019, the Company received $0.4 million of cash proceeds from Australia and $0.4 million of cash proceeds from the United Kingdom pursuant to research and development tax credits.
As of March 10, 2020, the Company had 10.7 million common shares outstanding.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for cancer (INB03), Alzheimers (XPro595), and NASH (LIVNate). The Innate Immune Priming Platform includes INKmune aimed at priming the patients NK cells to eliminate minimal residual disease in patients with cancer. INmune Bios product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit http://www.inmunebio.com.
Information about Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03 and XPro1595 are still in clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Companys ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Companys business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Companys filings with the Securities and Exchange Commission, including the Companys Annual Report on Form 10-K, the Companys Quarterly Reports on Form 10-Q and the Companys Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
INmune Bio Contact: David Moss, CFO (858) 964-3720 DMoss@INmuneBio.com
Investor Contact: James Carbonara (646) 755-7412 James@haydenir.com
CONSOLIDATED BALANCE SHEETS (Unaudited) December 31, December 31, 2019 2018 ------------- ------------- ASSETS CURRENT ASSETS Cash $ 6,995,525 $ 186,204 Research and development tax credit receivable 568,139 592,215 Other tax receivable 77,225 37,382 Joint development cost receivable - 17,989 Prepaid expenses 97,623 15,552 Prepaid expenses related party 26,266 - - ----------- - ----------- TOTAL CURRENT ASSETS 7,764,778 849,342 - ----------- - ----------- Operating lease right of use asset related party 191,543 - Acquired in-process research and development intangible assets 16,514,000 16,514,000 - ----------- - ----------- TOTAL ASSETS $ 24,470,321 $ 17,363,342 - ----------- - ----------- LIABILITIES AND STOCKHOLDERS EQUITY CURRENT LIABILITIES Accounts payable and accrued liabilities $ 401,989 $ 553,221 Accounts payable and accrued liabilities related parties 290,102 270,545 Operating lease, current liability related party 8,288 - - ----------- - ----------- TOTAL CURRENT LIABILITIES 700,379 823,766 Long-term operating lease liability related party 160,164 - - ----------- - ----------- TOTAL LIABILITIES 860,543 823,766 - ----------- - ----------- COMMITMENTS AND CONTINGENCIES STOCKHOLDERS EQUITY Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares - - issued and outstanding Common stock, $0.001 par value, 200,000,000 shares authorized, 10,770,948 and 10,771 8,719 8,719,441 shares issued and outstanding, respectively Additional paid-in capital 44,833,703 25,446,196 Common stock issuable 50,000 4,676,000 Accumulated other comprehensive income (loss) (8,515 ) 6,529 Accumulated deficit (21,276,181 ) (13,597,868 ) TOTAL STOCKHOLDERS EQUITY 23,609,778 16,539,576 - ----------- - ----------- TOTAL LIABILITIES AND STOCKHOLDERS EQUITY $ 24,470,321 $ 17,363,342 - ----------- - -----------
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS FOR THE YEARS ENDED DECEMBER 31, 2019 AND 2018 (Unaudited) 2019 2018 ------------ ------------- REVENUE $ - $ - - ---------- - ----------- OPERATING EXPENSES General and administrative 6,016,056 9,085,100 Research and development 3,281,945 3,354,923 Gain on waiver of common stock issuable (1,542,000 ) - - ---------- - ----------- Total operating expenses 7,756,001 12,440,023 - ---------- - ----------- LOSS FROM OPERATIONS (7,756,001 ) (12,440,023 ) - ---------- - ----------- OTHER INCOME Interest income 77,688 - - ---------- - ----------- Total other income 77,688 - - ---------- - ----------- NET LOSS $ (7,678,313 ) $ (12,440,023 ) - ---------- - ----------- Net loss per common share basic and diluted $ (0.75 ) $ (1.43 ) Weighted average number of common shares outstanding basic and diluted 10,272,641 8,676,701
CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2019 AND 2018 (Unaudited) 2019 2018 ------------ ------------- CASH FLOWS FROM OPERATING ACTIVITIES: Net loss $ (7,678,313 ) $ (12,440,023 ) Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation 4,096,538 10,001,359 Gain on waiver of common stock issuable (1,542,000 ) - Changes in operating assets and liabilities: Research and development tax credit receivable 24,076 (485,349 ) Other tax receivable (39,843 ) 74,236 Joint development cost receivable 17,989 91,135 Prepaid expenses (82,071 ) 27,095 Prepaid expenses related party (26,266 ) 158,504 Accounts payable and accrued liabilities (151,232 ) 426,964 Accounts payable and accrued liabilities related parties 19,557 87,085 Operating lease liability related party (23,091 ) - - ---------- - ----------- Net cash used in operating activities (5,384,656 ) (2,058,994 ) - ---------- - ----------- CASH FLOWS FROM FINANCING ACTIVITIES: Net proceeds from sale of common stock 12,209,021 900,000 - ---------- - ----------- Net cash provided by financing activities 12,209,021 900,000 - ---------- - ----------- Impact on cash from foreign currency translation (15,044 ) (25,513 ) NET INCREASE (DECREASE) IN CASH 6,809,321 (1,184,507 ) CASH AT BEGINNING OF YEAR 186,204 1,370,711 - ---------- - ----------- CASH AT END OF YEAR $ 6,995,525 $ 186,204 - ---------- - -----------
Read the rest here:
INmune Bio, Inc. Reports Fourth Quarter and Full Year 2019 Results - Drug Pipeline Expands to Now Include Cancer, Alzheimer's Disease and NASH -...
- Jake Diekman throws BP session for Rangers | MLB.com - MLB.com - August 6th, 2017 [August 6th, 2017]
- Cerebral palsy: Symptoms, diagnosis, treatment - December 5th, 2017 [December 5th, 2017]
- Hypothalamus - the body's thermostat | ASU - Ask A Biologist - December 6th, 2017 [December 6th, 2017]
- When Stroke Affects the Thalamus - Stroke Connection ... - December 28th, 2017 [December 28th, 2017]
- The Endocrine System: Hypothalamus and Pituitary - December 28th, 2017 [December 28th, 2017]
- Hypothalamus - Anatomy, Blood supply and Function | Kenhub - December 28th, 2017 [December 28th, 2017]
- Ulcerative Colitis - Cedars-Sinai - January 6th, 2018 [January 6th, 2018]
- Ulcerative colitis - Treatment - NHS.UK - January 7th, 2018 [January 7th, 2018]
- Business Directory | Uptown Waterloo Business Improvement Area - January 8th, 2018 [January 8th, 2018]
- Will States Continue To Fund Stem Cell Research? : Shots ... - January 28th, 2018 [January 28th, 2018]
- Spinal Cord Injuries - emedicine.medscape.com - February 15th, 2018 [February 15th, 2018]
- Spinal Cord Injuries - spine.org - February 15th, 2018 [February 15th, 2018]
- Journal of Clinical & Experimental Cardiology - Open Access Journals - April 10th, 2018 [April 10th, 2018]
- Cardiology Treatment - Fortis Healthcare - April 10th, 2018 [April 10th, 2018]
- Biology Junction - April 12th, 2018 [April 12th, 2018]
- Managing Right Ventricular Failure in PAH: An Algorithmic ... - April 14th, 2018 [April 14th, 2018]
- Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in ... - April 22nd, 2018 [April 22nd, 2018]
- Cardiovascular Pharmacotherapeutics: William H. Frishman ... - May 13th, 2018 [May 13th, 2018]
- 13 Super Foods Good for Eczema - Top Eczema Treatments - May 15th, 2018 [May 15th, 2018]
- Diagnosis & Treatment of Parkinson's - ParkinsonsDisease.net - May 30th, 2018 [May 30th, 2018]
- Arizona Heart Rhythm Center - June 10th, 2018 [June 10th, 2018]
- Ayurvedic Medicines for Ulcerative Colitis | Natural ... - June 21st, 2018 [June 21st, 2018]
- Weinstein Cardiovascular Development and Regeneration Meeting - June 30th, 2018 [June 30th, 2018]
- Ulcerative Colitis Information Centre - July 31st, 2018 [July 31st, 2018]
- Sudden Death in Dogs - Pet Health Network | Pet Health ... - August 7th, 2018 [August 7th, 2018]
- Coronary Heart Disease - Ischaemic heart disease - British ... - August 21st, 2018 [August 21st, 2018]
- Cardiac Rehabilitation: Overview, History and Definition ... - August 25th, 2018 [August 25th, 2018]
- Difference between Cardiac Arrest and Respiratory Arrest ... - August 25th, 2018 [August 25th, 2018]
- ECM for Pericardial Closure - Aziyo - August 25th, 2018 [August 25th, 2018]
- Adult Mental Health | Georgia Department of Behavioral Health ... - September 6th, 2018 [September 6th, 2018]
- Mental Health | ECLKC - September 6th, 2018 [September 6th, 2018]
- Mental Health - The Church of Jesus Christ of Latter-day Saints - September 6th, 2018 [September 6th, 2018]
- Center for Vascular Biology - Home | UConn Health - September 22nd, 2018 [September 22nd, 2018]
- # Diabetes Stem Cell Research Diabetes Care Measures - September 30th, 2018 [September 30th, 2018]
- Cardiac Rhythm Disturbances | The Patient Guide to Heart ... - November 2nd, 2018 [November 2nd, 2018]
- Arrhythmia | Cleveland Clinic - November 2nd, 2018 [November 2nd, 2018]
- Hyperbaric Oxygen Therapy for Wound Healing | Johns ... - November 13th, 2018 [November 13th, 2018]
- NIMH Home - November 24th, 2018 [November 24th, 2018]
- What is an interventional cardiologist? | Heart Surgeries ... - November 26th, 2018 [November 26th, 2018]
- Molecular Cardiology Research Institute Boston | Tufts ... - November 29th, 2018 [November 29th, 2018]
- Lower vascular plant | botany | Britannica.com - December 7th, 2018 [December 7th, 2018]
- Welcome to the ABG Tutorial Welcome to Hansen - December 12th, 2018 [December 12th, 2018]
- Cardiac catheterization - Wikipedia - December 12th, 2018 [December 12th, 2018]
- Stem Cell Research & Therapy | Home page - December 22nd, 2018 [December 22nd, 2018]
- Journal of Stem Cell Research and Therapy- Open Access ... - December 22nd, 2018 [December 22nd, 2018]
- Stem-cell therapy - Wikipedia - December 22nd, 2018 [December 22nd, 2018]
- Cardiology and Interventional Cardiology - December 23rd, 2018 [December 23rd, 2018]
- Rhode Island Interventional Cardiology | Cardiovascular ... - December 23rd, 2018 [December 23rd, 2018]
- Interventional Cardiology Certification Policies | ABIM.org - December 23rd, 2018 [December 23rd, 2018]
- Interventional Cardiology - Boston Scientific - December 23rd, 2018 [December 23rd, 2018]
- 9 Benefits of Human Growth Hormone (Along with Side ... - December 27th, 2018 [December 27th, 2018]
- Growth hormone deficiency - Wikipedia - December 27th, 2018 [December 27th, 2018]
- Dr. Lorrie Kirshenbaum, Cardiac Gene Biology | St ... - January 28th, 2019 [January 28th, 2019]
- Cardiomyopathy - CardioSmart - February 8th, 2019 [February 8th, 2019]
- Centenary Institute | Medical Research, Life Saving Research - February 24th, 2019 [February 24th, 2019]
- Cardiovascular Medicine | Department of Medicine - March 29th, 2019 [March 29th, 2019]
- Rapid Test Market 2019 with Recent Trends, Revenue, Demand and Top Manufactures- Bureau Veritas, SGS SA, Intertek Group plc, Eurofins Scientific -... - October 11th, 2019 [October 11th, 2019]
- Medical Imaging Equipment Market Research Report 2019: Global Industry Analysis, Business Development, Size, Share, Trends, Future Growth, Forecast To... - October 11th, 2019 [October 11th, 2019]
- Analysis on the Global DNA Read, Write & Edit Market, 2017-2019 and Forecast to 2024 - Yahoo Finance - October 11th, 2019 [October 11th, 2019]
- Cardiac Surgery Instruments Market is Expected to Tread a Steady Growth Trajectory by Clocking a CAGR of 5.9% from 2017 to 2022 - Health News Office - October 24th, 2019 [October 24th, 2019]
- PEDIATRIC MEDICAL DEVICES MARKET IS PROJECTED TO EXPAND AT A CAGR OF 8.0% FROM 2018 TO 2026 - Health News Office - November 1st, 2019 [November 1st, 2019]
- myTAIHEART Test Provides Evidence for Injury from Biopsy of Heart Transplant Recipients Cardiology2.0 - Cardiology2.0 - November 1st, 2019 [November 1st, 2019]
- Mental health and your heart - British Heart Foundation - November 19th, 2019 [November 19th, 2019]
- BUZZ-U.S. STOCKS ON THE MOVE-Cango, Gulfport Energy, Abiomed, Standard Diversified, Wanda Sports, Eidos - Nasdaq - November 19th, 2019 [November 19th, 2019]
- Cost Analysis of COPD Exacerbations and Cardiovascular Events in SUMMIT - AJMC.com Managed Markets Network - November 19th, 2019 [November 19th, 2019]
- Hundreds walk to defeat ALS in Ancient City - St. Augustine Record - November 22nd, 2019 [November 22nd, 2019]
- Living with Lung Cancer: The Silver Linings - Curetoday.com - November 22nd, 2019 [November 22nd, 2019]
- Building the human spinal cord atlas - SynBioBeta - November 22nd, 2019 [November 22nd, 2019]
- The Week That Wasn't: Keto and the Flu, Human Cyborg, Duvet Disease - Medscape - November 22nd, 2019 [November 22nd, 2019]
- ALS advance offers hope for those diagnosed with deadly disease - WRAL.com - November 22nd, 2019 [November 22nd, 2019]
- ALS Stem Cell Therapy Developer Seeks Amendment to its AstroRx Trial - ALS News Today - November 22nd, 2019 [November 22nd, 2019]
- Former Boston Globe writer, current NHL executive Snow diagnosed with ALS | College Hockey - USCHO - December 23rd, 2019 [December 23rd, 2019]
- AB Science announces the publication of new results in the peer-reviewed journal Glia that further support masitinib's potential mode of action in ALS... - December 23rd, 2019 [December 23rd, 2019]
- Christmas in the City thrills homeless families, takes on poignancy with founders ALS diagnosis - The Boston Globe - December 23rd, 2019 [December 23rd, 2019]
- Amylyx Pharmaceuticals Announces AMX0035 Demonstrated Statistically Significant Treatment Benefit for People with ALS in the CENTAUR Trial - Business... - December 23rd, 2019 [December 23rd, 2019]
- RADICAVA (edaravone) - December 23rd, 2019 [December 23rd, 2019]
- List of Amyotrophic Lateral Sclerosis Medications (5 Compared ... - December 23rd, 2019 [December 23rd, 2019]
- Neuropore Completes Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson's Disease and... - January 14th, 2020 [January 14th, 2020]
- Comprehensive Analysis on Prostacyclin Market based on types and application - Technology Magazine - January 18th, 2020 [January 18th, 2020]
- N.J. karate legend who inspired thousands loses battle with ALS - NJ.com - January 18th, 2020 [January 18th, 2020]